Meeting to be held in New York on November 12-13 hosted by Oppenheimer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals price target lowered to $35 from $40 at Oppenheimer
- ARS Pharmaceuticals Reports Strong Q3 2025 Growth
- Ars Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Promising Outlook for ARS Pharmaceuticals: Buy Rating Affirmed by Lachlan Hanbury Brown
- ARS Pharmaceuticals Reports Q3 2025 Financial Results